✦ LIBER ✦

Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients

✍ Scribed by Chadi Nabhan; Nancy Davis; Jacob D. Bitran; Angel Galvez; Walter Fried; Kathy Tolzien; Susan Foss; Wendy M. Dewey; Parameswaran Venugopal

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 149 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25603

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of rituximab and bortezomi

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

✍ Robert A. Baiocchi; Lapo Alinari; Mark E. Lustberg; Thomas S. Lin; Pierluigi Por 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 1 views

Cladribine in the treatment of advanced

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma

✍ Anil Tulpule; Gary Schiller; Laura A. Harvey-Buchanan; Myung Lee; Byron M. Espin 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## BACKGROUND. Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analog with cytotoxic activity against both resting and proliferating cells. Clinical studies with cladribine have reported antitumor activity against various hematologic malignancies.

Phase II study of oxaliplatin in patient

Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma

✍ Yasuhiro Oki; Peter McLaughlin; Barbara Pro; Fredrick B. Hagemeister; Archie Ble 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Phase 2 study of gemcitabine in combinat

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

✍ Yasuhiro Oki; Barbara Pro; Luis E. Fayad; Jorge Romaguera; Felipe Samaniego; Fre 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 2 views

## Abstract ## BACKGROUND. The management of recurrent or refractory Hodgkin lymphoma (HL) remains challenging. The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL. ## METHODS. Patients were

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Pixantrone dimaleate in combination with

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma : Phase 1 study with a dose-expansion cohort

✍ Tomasz P. Srokowski; James E. Liebmann; Manuel R. Modiano; Gary I. Cohen; Barbar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

## Abstract ## BACKGROUND: Pixantrone dimaleate (pixantrone) has been shown to have antitumor activity in leukemia and lymphoma in vitro models and to lack delayed cardiotoxicity associated with mitoxantrone in animal models. FND‐R, a combination regimen of fludarabine, mitoxantrone, dexamethasone